Y Biologics
Launch date
Employees
Market cap
$161.0b
Enterprise valuation
$148.8b (Public information from Sep 2024)
Share price
KRW11450 338840.KQ
Company register number 3148195083
Daejeon South Korea (HQ)
Financials
Estimates*
| KRW | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|
| Revenues | 6.7b | 4.8b | 4.2b | 3.5b |
| % growth | - | (28 %) | (14 %) | (16 %) |
| EBITDA | (6.4b) | (14.7b) | (15.6b) | (18.7b) |
| % EBITDA margin | (96 %) | (303 %) | (375 %) | (537 %) |
| Profit | (10.0b) | (17.1b) | (18.8b) | (20.9b) |
| % profit margin | (149 %) | (352 %) | (453 %) | (600 %) |
| R&D budget | 8.9b | 12.6b | 11.9b | 6.7b |
| R&D % of revenue | 132 % | 260 % | 288 % | 191 % |
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | N/A | - | |
* | KRW30.0b | Late VC | |
* | N/A | N/A | IPO |
| Total Funding | $25.2m | ||
Related Content
Recent News about Y Biologics
EditTech stack
Tech stackLearn more about the technologies and tools that this company uses.